News
BMS agrees deal worth up to $1.56bn for Agenus' TIGIT cancer...
Bristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to a cancer antibody still in the labs of US biotech Agenus, which blocks the